Redx Pharma is a drug discovery and development company formed in 2010. It is focused on improving the characteristics of existing drug classes to create best-in-class new drugs in the areas of cancer, infection and autoimmune disease. The company's work has been endorsed by partnerships with global pharmaceutical companies and the NHS.

Find out more

Latest News

Redx confirms potential role for Porcupine inhibitor in cancer immunotherapy
20 September 2016

Redx Pharma Plc is pleased to confirm that its lead cancer treatment, the Porcupine inhibitor (RXC004), has a potential role in cancer immunotherapy. Redx scientists have demonstrated that the Porcupine inhibitor could have a crucial role in improving the immune system response of some cancer patients when used in combination with an existing immunotherapy, anti-programmed cell death-1 (anti-PD-1).

Anti-PD-1 therapy activates the immune system to recognise and attack tumours. While treatment with PD-1 inhibitors, also known as Checkpoint inhibitors, is a significant breakthrough in cancer treatment, not all patients respond.

Redx has been testing a combination therapy that uses both the Porcupine inhibitor RXC004 and an anti-PD-1 antibody in a cancer model. The data demonstrates that the combination therapy significantly improves the ratio of favourable T-cells, which attack tumours, to the immunosuppressive T-cells that allow tumours to grow unrecognised, when compared to only using an anti-PD-1 therapy. This suggests that a combination therapy could potentially improve patient response rates.

Read more

We're Hiring

As a fast-growing dynamic business we are continually looking for talented people to join our team.

Work for us

In The Media

19 September 2016
Redx tipped to triple…

Interactive Investor

11 September 2016
Redx Pharma could soar as new drugs come on stream…

Daily Mail Midas Share Tip

Our Subsidiary Companies

Discovering and developing new therapeutics in the area of infectious disease generating a pipeline of novel antibacterial & antiviral drugs.

View details

Modulating the immune system with novel small molecules to treat a range of diseases with high unmet medical need.

View details

Delivering multiple development candidates across a range of mechanistic approaches in cancer treatment.

View details